Shkreli dismisses the current hype around using AI for molecule generation as 'LARP' (Live Action Role-Playing). He argues that inventing a molecule is only 10% of the drug development process and the real, unsolved challenge is identifying novel biological targets, which he believes is where AI, specifically LLMs trained on all medical literature, could have the most impact.
Shkreli views the pharmaceutical industry as a fragmented, modular business ripe for arbitrage. He defends his infamous price hike of a 70-year-old drug as a rational business decision based on the fundamental capitalist principle of pricing power, especially for orphan drugs with small patient populations.
Reflecting on his fraud conviction, Shkreli maintains his innocence, claiming he was a target of 'lawfare' due to his public persona. He discusses his prison experience, the psychological toll of being denied internet access, and draws parallels to Sam Bankman-Fried's situation, offering a critical view of a justice system he believes is stacked against defendants.
Shkreli contrasts the capital-intensive nature of biotech, where a 10% founder equity stake is a success, with the software industry. His journey from hedge funds to pharma to his current financial software venture showcases a consistent, hands-on approach of diving deep into the technical details of any industry he enters, from medicinal chemistry to PyTorch.
Keep pulling the thread on Martin Shkreli.